Status: Recruiting
Phase Ib Clinical Study of Keynatinib
The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R/R-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.
Participants needed: 75
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Medolution Ltd.Updated: Jan 22, 2025Locations: 4
Eligibility criteria
Unlimited gender, age ≥ 18 years (including critical value)-Cohort 1/2/3; [+21]
Cohort 1: R/R-PCNSL [+73]